Author(s): Esperança-Martins, Miguel ; F. Duarte, Iola ; Rodrigues, Mara ; Soares do Brito, Joaquim ; López-Presa, Dolores ; Costa, Luís ; Fernandes, Isabel ; Dias, Sérgio
Date: 2022
Persistent ID: http://hdl.handle.net/10773/36135
Origin: RIA - Repositório Institucional da Universidade de Aveiro
Subject(s): Biomarkers; Humans; Metabolome; Metabolomics; Sarcoma; Soft Tissue Neoplasms
Soft tissue sarcomas (STS) prognosis is disappointing, with current treatment strategies being based on a "fit for all" principle and not taking distinct sarcoma subtypes specificities and genetic/metabolic differences into consideration. The paucity of precision therapies in STS reflects the shortage of studies that seek to decipher the sarcomagenesis mechanisms. There is an urge to improve STS diagnosis precision, refine STS classification criteria, and increase the capability of identifying STS prognostic biomarkers. Single-omics and multi-omics studies may play a key role on decodifying sarcomagenesis. Metabolomics provides a singular insight, either as a single-omics approach or as part of a multi-omics strategy, into the metabolic adaptations that support sarcomagenesis. Although STS metabolome is scarcely characterized, untargeted and targeted metabolomics approaches employing different data acquisition methods such as mass spectrometry (MS), MS imaging, and nuclear magnetic resonance (NMR) spectroscopy provided important information, warranting further studies. New chromatographic, MS, NMR-based, and flow cytometry-based methods will offer opportunities to therapeutically target metabolic pathways and to monitorize the response to such metabolic targeting therapies. Here we provide a comprehensive review of STS omics applications, comprising a detailed analysis of studies focused on the metabolic landscape of these tumors.
